Fixed Panels

Our most comprehensive assay panel, screening for 520 clinically relevant genes as determined and recommended by the National Comprehensive Cancer Network. This gene panel screens for the majority of all actionable genetic mutations of interest within the oncology therapeutic development space.

Compatible with both tissue (Oncoscreen IO) and blood-based (Oncocompass IO) samples, the breadth of this diagnostic test allows for evaluation of complex biomarkers such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD) as well as detection of specific rare mutations such as NTRK1-3 rearrangements, ALK fusions, and KRAS point mutations for treatment guidance of both targeted therapies and immunotherapies.

TMB (FDA approved June 2020) as a biomarker measures the total number of mutations found in DNA in cancer cells, and thus, gives predictive and prognostic value for determining cancer therapy. As this is our most comprehensive panel, Oncoscreen IO has applications for almost all cancer types. It can provide accurate genomic profiling for both clinical trial patient selection as well as therapy response monitoring.

Cancer Types and Genetic Biomarkers

Pan Cancer

  • FGFR
  • Tumor Mutational Burden (TMB)
  • Microsatellite Instability (MSI)

Colorectal

  • Somatic pole exonuclease domain mutations
  • BRAF
  • MLH1
  • MSH2
  • MSH6
  • PMS2
  • MUTYH
  • TP53
  • KRAS
  • APC
  • SMAD4
  • AXIN1
  • GREM1
  • PIK3CA

Prostate

  • KRAS point mutations
  • PIKC3A
  • BRCA1
  • BRCA2
  • ATM
  • BRIP1
  • CDK12
  • CHEK1
  • CHEK2
  • FANCL
  • PALB2
  • PPP2R2A
  • RAD51B
  • RAD51C
  • RAD51D
  • RAD54L

Breast

  • BRCA1
  • BRCA2
  • PARP1
  • PARP2
  • ATM
  • PALB2
  • TP53
  • CHEK2
  • PIK3CA
  • PTEN
  • CDH1
  • NBN
  • NF1
  • STK11
  • BARD1
  • BRIP1
  • MLH1
  • MSH2
  • MSH6
  • PMS2
  • EPCAM
  • RAD51C
  • RAD51D

Lung

  • EGFR T790M mutations (the most prevalent mechanism for acquiring EGFR TKI resistance)
  • C-Met Exon 14 Skipping mutations
  • MET amplification
  • ERBB2 amplifications
  • ALK fusions
  • KRAS point mutations
  • PIKC3A

Melanoma

  • BRAF V600
  • GNAQ
  • GNA11
  • NRAS
  • KIT
  • BAP1
  • SF3B1
  • EIF1AX

A more focused panel, Oncoscreen Target screens for an array of 168 clinically actionable predictive biomarkers. It has the capability to assess the complex biomarker MSI, as well as genetic mutations including those of EGFR, ATM, and MET, as well as genetic rearrangements including those of NTRK1-3, ROS1, and RET. It is available for diagnosis of both tissue (Oncoscreen Target) and blood-based (Oncocompass Target) samples. The advantages of diagnosing ctDNA include not having to take multiple biopsies, its minimal invasiveness, and being able to identify for resistance along therapeutic treatment.

This panel has applications for a large variety of cancer types including melanoma, lung, breast, prostate, and liver cancer. It can provide comprehensive genomic profiling for clinical trial patient selection as well as therapy response monitoring and is currently being used for biomarker detection for Tagrisso® (osimertinib) and Afatinib.

Cancer Types

Lung

  • EGFR T790M mutations (the most prevalent mechanism for acquiring EGFR TKI resistance)
  • c-Met Exon 14 Skipping mutations
  • MET amplifications
  • ERBB2 amplifications
  • ALK fusions
  • KRAS point mutations
  • PIKC3A

Breast

  • BRCA1
  • BRCA2
  • PARP1
  • ATM
  • PALB2
  • TP53
  • CHEK2
  • STK11
  • PIK3CA
  • PTEN
  • NBN
  • NF1
  • BARD1
  • BRIP1
  • MLH1
  • MSH2
  • MSH6
  • PMS2
  • RAD51C
  • RAD51D

Colorectal

  • Somatic pole exonuclease domain mutations
  • BRAF
  • MLH1
  • MSH2
  • MSH6
  • PMS2
  • MUTYH
  • TP53
  • KRAS
  • APC
  • PIK3CA

Prostate

  • BRCA1
  • BRCA2
  • ATM
  • CHEK2

Melanoma

  • BRAF V600
  • NRAS
  • KIT

Our OncoScreen Focus panel is used primarily in Lung Cancer applications as a test to screen prospective patients for clinical trials, help guide therapy selection, and also for studies around the world for lung cancer researchers. It screens for 13 of the most actionable genes highly involved in lung cancers including EGFR, MET, and ROS1. It is available for diagnosis for tissue-based samples.

Cancer Types

Lung

  • EGFR T790M mutations (the most prevalent mechanism for acquiring EGFR TKI resistance)
  • c-Met Exon 14 Skipping mutations
  • MET amplifications
  • ERBB2 amplifications
  • ALK fusions
  • KRAS point mutations
  • PIKC3A

Colorectal

  • BRAF
  • KRAS
  • PIK3CA

List of genes

  • EGFR
  • MET
  • ERBB2
  • HRAS
  • KIT
  • ALK
  • BRAF
  • KRAS
  • PDGFRA
  • ROS1
  • RET
  • NRAS
  • PIK3CA

Contact Us

We look forward to hearing from you. Whether you are an academic collaborator or a potential biopharma partner, feel free to reach out and our team will get back to you as soon as possible.

Call Us

(949)-732-6484

Send Us A Message